Capsaicin 8% topical patch (qutenza)-a review of the evidence

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 25, Issue 1, 2011, Pages 32-41

  Jones, Virginia M ^a   Moore, Katrina A ^c   Peterson, David M ^a,b  

^a Department of Pharmacy Services   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NONE

Author keywords

Capsaicin; chronic pain; herpes zoster treatment; neuropathic pain; postherpetic neuralgia; topical

Indexed keywords

ANALGESIC AGENT; CAPSAICIN; CYTOCHROME P450; VANILLOID RECEPTOR 1;

ANALGESIA; ANESTHESIA; APPLICATION SITE DRYNESS; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; BRONCHITIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; HUMAN; HYPERTENSION; META ANALYSIS; NAUSEA; NOCICEPTION; PAIN ASSESSMENT; PAIN PARAMETERS; POSTHERPETIC NEURALGIA; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHINOPHARYNGITIS; SEX DIFFERENCE; SINGLE DRUG DOSE; SINUSITIS; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, CUTANEOUS; CAPSAICIN; CLINICAL TRIALS AS TOPIC; HUMANS; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; SENSORY SYSTEM AGENTS; TRANSDERMAL PATCH; TRPV CATION CHANNELS;

EID: 79953200816     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2010.547561     Document Type: Review

References (27)

1. Neuroges X. Qutenza (capsaicin) 8% patch [product information]. San Mateo CA: NeurogesX Inc 2009.
2. Center for Drug Evaluation and Research. Summary Review. Application 22-395. Food and Drug Administration Department of Health and Human Services. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022395s000Sumr. pdf. Accessed September 29, 2010.
3. Endo Pharmaceuticals Inc. Lidoderm (lidocaine patch 5%) [product information]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010.
4. Pfzer Inc. Neurontin (gabapentin) [productinformation]. New York, NY: Pfzer Inc; 2009.
5. Pfzer Inc. Lyrica (pregabalin) [product information]. New York, NY: Pfzer Inc; 2009.
6. Simpson DM, Brown S, Tobias J. Controlled trial of highconcentration capsaicin patch for treatment ofpainful HIV neuropathy. Neurology. 2008;70:2305-2313.
7. Simpson DM, Estanislao L, Brown SJ, Sampson J. An openlabel pilot study of high-concentration capsaicin patch in painful HIV neuropathy.JPain Symptom Manage. 2008;35:299-306. (Pubitemid 351284504)
8. Johnson RW Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21-26.
9. Weaver BA The burden of herpes zoster and postherpetic neuralgia in the United States. JAm Osteopath Assoc. 2007;107(3 Suppl 1):S2-S7. (Pubitemid 46827879)
10. Harpaz R, Ortega-Sanchez IR, Seward JF Prevention ofherpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30; quiz CE32-CE34.
11. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959-965. (Pubitemid 39287901)
12. Thakur R, Kent JL, Dworkin RH Herpes zoster and posther-petic neuralgia. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonica's Management of Pain. 4th ed. Baltimore, MD: Wolters Kluwer; Lippincott Williams & Wilkins; 2010:338-357.
13. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169. (Pubitemid 44581463)
14. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2:e164.
15. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of pos-therpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106-1112.
16. Kennedy WR, Vanhove GF, Lu SP, et al. A randomized, con-trolled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fber density and sensory function in healthy volunteers. J Pain. 2010;11:579-587.
17. Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neu-ropathicpain. Ther Drug Monit. 2009;31:502-510.
18. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: par-allel loss of epidermal nerve fbers and pain sensation. Pain. 1999;81:135-145. (Pubitemid 29199909)
19. Reilly CA, Yost GS. Metabolism of capsaicinoids by P450 en-zymes: a review of recent fndings on reaction mechanisms, bio-activation, and detoxifcation processes. Drug Metab Rev. 2006;38:685-706. (Pubitemid 44903263)
20. Center for Drug Evaluation and Research. Medical Review(s). Application 22-395. Food and Drug Administration, Depart-ment of Health and Human Services. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/ 022395s000Medr. pdf. Accessed September 29, 2010.
21. Backonja M, Dunteman E, Irving GA, et al. One 60-minute application of a high-concentration capsaicin patch (NGX-4010) signifcantly reduced pain for up to 3 months in patients with postherpetic neuralgia: results from a randomized, double-blind, controlled Phase 3 study [abstract]. Presented at 60thAn-nual Meeting of the American Academy of Neurology (AAN); Chicago, IL; April 12-19, 2008.
22. Backonja M, Dunteman E, Irving GA, et al. One-hour ap-plication of NGX-4010, a high-concentration capsaicin patch, in postherpetic neuralgia [abstract]. Presented at 19th An-nual Meeting of the American Academy of Pain Management (AAPM); Nashville, TN; September 8-11, 2008.
23. Irving GA, Blonsky ER, Backonja MM, Lu SP, Vanhove GF, Tobias J. An effcacy and safety analysis of a single one-hour application ofNGX-4010 in patients with postherpetic neural-gia: results of a randomized, double-blind, 12-week, controlled study [abstract]. Presented at 12th World Congress on Pain; Glasgow, Scotland; August 17-22, 2008.
24. Backonja MM, Malan TP, Vanhove GF, Tobias JK. NGX-4010, a high-concentration capsaicin patch, for the treat-ment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med. 2010;11:600-608.
25. Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A Multicenter, randomized, double-blind, controlled dose fnding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.JPain. Jul 22 2010;11(10):972-982.
26. Simpson DM, Gazda S, Brown S, et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage. 2010;39:1053-1064.
27. Neuroges X. Qutenza (capsaicin) 8% patch [dossier]. San Ma-teo, CA: NeurogesX, Inc.; 2009.